Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Combined With Obinutuzumab in Treatment-Naive CLL
NCT05950997Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by Jiangsu Provincial People's Hospital. Started Apr 2024; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05950997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950997.